1y return+101.1%S&P 500 +20.9%
3y return+177.3%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since March 31, 2022: $328 against $165 in the S&P 500.2
Frazier Life Sciences Management, L.P.S&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| MIRMMirum Pharmaceuticals Inc | $899.1M | 19.6% | |
| Newamsterdam Pharma CompanyCUSIP N62509109 | $613.0M | 13.3% | +6.8% |
| ERASErasca Inc | $457.5M | 10.0% | +1.2% |
| MBXMbx Biosciences Inc | $367.2M | 8.0% | |
| ARQTArcutis Biotherapeutics Inc | $258.9M | 5.6% | |
| TRVITrevi Therapeutics Inc | $185.4M | 4.0% | |
| KRYSKrystal Biotech Inc | $178.9M | 3.9% | |
| MAZEMaze Therapeutics Inc | $150.2M | 3.3% | +10.2% |
| PHATPhathom Pharmaceuticals Inc | $135.3M | 2.9% | |
| PVLAPalvella Therapeutics Inc Ne | $134.8M | 2.9% | |
| BBIOBridgebio Pharma Inc | $115.3M | 2.5% | −55.1% |
| IRONDisc Medicine Inc | $99.1M | 2.2% | |
| CYTKCytokinetics Inc | $98.8M | 2.2% | |
| DYNDyne Therapeutics Inc | $70.0M | 1.5% | |
| Ascendis Pharma A/sCUSIP 04351P101 | $60.1M | 1.3% | +68.9% |
| SVRASavara Inc | $59.9M | 1.3% | |
| PBLSParabilis Medicines Inc | $52.6M | 1.1% | New |
| AURAAura Biosciences Inc | $50.4M | 1.1% | +39.2% |
| ACHVAchieve Life Science Inc | $49.7M | 1.1% | New |
| VORVor Biopharma Inc | $46.8M | 1.0% | |
| ALLOAllogene Therapeutics Inc | $46.7M | 1.0% | +491.2% |
| TARSTarsus Pharmaceuticals Inc | $45.9M | 1.0% | |
| BCRXBiocryst Pharmaceuticals Inc | $40.1M | 0.9% | |
| Alkermes PLCCUSIP G01767105 | $36.7M | 0.8% | |
| ACADAcadia Pharmaceuticals Inc | $36.4M | 0.8% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| PVLAPalvella Therapeutics Inc Ne | December 31, 2024 | +1173.5% | $134.8M |
| TRVITrevi Therapeutics Inc | June 30, 2022 | +563.7% | $185.4M |
| KRYSKrystal Biotech Inc | March 31, 2022 | +458.6% | $178.9M |
| MIRMMirum Pharmaceuticals Inc | March 31, 2022 | +431.7% | $899.1M |
| BBIOBridgebio Pharma Inc | March 31, 2023 | +349.2% | $115.3M |
| TARSTarsus Pharmaceuticals Inc | March 31, 2022 | +274.2% | $45.9M |
| Newamsterdam Pharma CompanyCUSIP N62509109 | December 31, 2022 | +222.1% | $613.0M |
| MAZEMaze Therapeutics Inc | March 31, 2025 | +171.0% | $150.2M |
| CYTKCytokinetics Inc | June 30, 2025 | +157.8% | $98.8M |
| MBXMbx Biosciences Inc | September 30, 2024 | +112.5% | $367.2M |
Sold off last quarter
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $99.9M
- RVMDRevolution Medicines Inc was $65.7M
- AGIOAgios Pharmaceuticals Inc was $42.5M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +20.6% | +14.8% |
| March 31, 2026 | −4.8% | −4.6% |
| December 31, 2025 | +30.3% | +2.4% |
| September 30, 2025 | +34.4% | +7.8% |
| June 30, 2025 | +7.7% | +10.5% |
| March 31, 2025 | −5.7% | −4.6% |
| December 31, 2024 | −2.1% | +2.1% |
| September 30, 2024 | +15.4% | +5.4% |
| June 30, 2024 | −8.0% | +4.0% |
| March 31, 2024 | +21.0% | +10.0% |
| December 31, 2023 | +19.9% | +11.2% |
| September 30, 2023 | −10.0% | −3.6% |
| June 30, 2023 | +16.8% | +8.3% |
| March 31, 2023 | −11.2% | +7.0% |
| December 31, 2022 | +11.3% | +7.1% |
| September 30, 2022 | +11.8% | −5.3% |
| June 30, 2022 | −8.4% | −16.5% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Frazier Life Sciences Management, L.P. Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1892134&type=13F-HR&dateb=&owner=include&count=40CIK 1892134
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1892134/000189213426000003/Filed August 14, 2026 · accession 0001892134-26-000003